The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Open accessAbstract
Cancer therapies will increasingly be utilized in combination to treat advanced malignancies so as to increase their long-term efficacy in a greater proportion of patients. In particular, much attention has focused on developing targeted therapies that inhibit the PI3K-AKT-mTOR signaling network which is dysregulated in many cancer types. In addition, there is now a growing appreciation that targeting of these pathways can impact not only on cancer cells, but also host immunity. The clinical success of cancer immunotherapies targeting T-cell immune checkpoint receptors PD-1/PD-L1 has demonstrated the importance of immunoevasion as a hallmark of cancer. In this review, we discuss how PI3K-AKT-mTOR inhibitors target cancer cell biology, attenuate immune cell effector function and modulate the tumor microenvironment. We next discuss how the immunomodulatory potential of these inhibitors can be exploited through rational combinations with immunotherapies and targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Self-citationPD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,202
T cell metabolism drives immunity
Buck, M. D., O’Sullivan, D., & Pearce, E. L. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151159 · Cited by 1,179
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
PI3K signalling: the path to discovery and understanding
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3290 · Cited by 987
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Self-citationImproved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Self-citationBengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
PI3K in lymphocyte development, differentiation and activation
Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1056 · Cited by 810
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
Tumor Immunotherapy Directed at PD-1
Ribas, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1205943 · Cited by 683
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
Divecha, N., & Irvine, R. F. (1995) · Cell · doi:10.1016/0092-8674(95)90409-3 · Cited by 567
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
T-bet: a bridge between innate and adaptive immunity
Lazarevic, V., Glimcher, L. H., & Lord, G. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3536 · Cited by 486
Dendritic Cell Vaccines for Cancer Immunotherapy
Timmerman, M., & Levy, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.507 · Cited by 485
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
PD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405
Hutson, T. E., Escudier, B., Esteban, E., Bjarnason, G. A., Lim, H. Y., Pittman, K. B., Senico, P., Niethammer, A., Lu, D. R., Hariharan, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3961 · Cited by 404
Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Crompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R. L., Tran, E., Hanada, K.-I., Yu, Z., Palmer, D. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2277 · Cited by 345
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C., Sancho, S., Walker, L. S. K., Vanhaesebroeck, B., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6598 · Cited by 303
Angelosanto, J. M., Blackburn, S. D., Crawford, A., & Wherry, E. J. (2012) · Journal of Virology · doi:10.1128/jvi.00889-12 · Cited by 285
Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065821 · Cited by 266
TOR complex 2: a signaling pathway of its own
Cybulski, N., & Hall, M. N. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.09.004 · Cited by 265
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
O'Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., Keating, M., Mitra, S., Holes, L., Yu, A. S., et al. (2015) · Blood · doi:10.1182/blood-2015-03-630947 · Cited by 241
Posch, C., Moslehi, H., Feeney, L., Green, G. A., Ebaee, A., Feichtenschlager, V., Chong, K., Peng, L., Dimon, M. T., Phillips, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216013110 · Cited by 234
Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., & Hersey, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123410 · Cited by 230
Ying, H., Elpek, K. G., Vinjamoori, A., Zimmerman, S. M., Chu, G. C., Yan, H., Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0031 · Cited by 223
The emerging multiple roles of nuclear Akt
Martelli, A. M., Tabellini, G., Bressanin, D., Ognibene, A., Goto, K., Cocco, L., & Evangelisti, C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.08.017 · Cited by 198
Akt3-Mediated Resistance to Apoptosis in B-RAF–Targeted Melanoma Cells
Shao, Y., & Aplin, A. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4471 · Cited by 194
Role of PI3K/Akt signaling in memory CD8 T cell differentiation
Kim, E. H., & Suresh, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00020 · Cited by 182
和田, 純., Suzuki, H. Y., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., Koga, K., Nakamura, M., Tanaka, M., Morisaki, T., et al. (2009) · PubMed · Cited by 169
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Eid, R. A., Samara, R. N., Ozbun, L. L., Abdalla, M. Y., Berzofsky, J. A., Friedman, K. M., Mkrtichyan, M., & Khleif, S. N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0095 · Cited by 167
Activity of any class IA PI3K isoform can sustain cell proliferation and survival
Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A., & Vanhaesebroeck, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906461107 · Cited by 166
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Dumble, M. L., Crouthamel, M., Zhang, S., Schaber, M. D., Levy, D. S., Robell, K. A., Liu, Q., Figueroa, D. J., Minthorn, E. A., Seefeld, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100880 · Cited by 151
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies, A. M., & Long, G. V. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70072-5 · Cited by 145
Toward rapamycin analog (rapalog)-based precision cancer therapy
Meng, L., & Zheng, X. F. S. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.68 · Cited by 141
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Pérez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M., Bollag, G. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 141
Chakrabarty, A., Bhola, N. E., Sutton, C., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2440 · Cited by 130
Brachmann, S. M., Kleylein-Sohn, J., Gaulis, S., Kauffmann, A., Blommers, M. J. J., Kazic-Legueux, M., Laborde, L., Hattenberger, M., Stauffer, F., Vaxelaire, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1021 · Cited by 121
van der Waart, A. B., van de Weem, N. M. P., Maas, F., Kramer, C. S. M., Kester, M. G. D., Falkenburg, J. H. F., Schaap, N. P., Jansen, J. H., van der Voort, R., Gattinoni, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578583 · Cited by 116
Münster, P. N., Aggarwal, R. R., Hong, D. S., Schellens, J. H. M., van der Noll, R., Specht, J. M., Witteveen, P. O., Werner, T. L., Dees, E. C., Bergsland, E. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1665 · Cited by 114
PTEN functions as a melanoma tumor suppressor by promoting host immune response
Dong, Y., Richards, J.-A., Gupta, R., Aung, P. P., Emley, A., Kluger, Y., Dogra, S. K., Mahalingam, M., & Wajapeyee, N. (2014) · Oncogene · doi:10.1038/onc.2013.409 · Cited by 113
Robert, C., Ribas, A., Hamid, O., DAUD, A. I., Wolchok, J. D., Joshua, A. M., Hwu, W., Weber, J. S., Gangadhar, T. C., Joseph, R. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9503 · Cited by 108
Activation of Akt as a Mechanism for Tumor Immune Evasion
Noh, K. H., Kang, T. H., Kim, J. H., Pai, S. I., Lin, K. Y., Hung, C., Wu, T. ‐., & Kim, T. W. (2008) · Molecular Therapy · doi:10.1038/mt.2008.255 · Cited by 98
Papadopoulos, K. P., Tabernero, J. M., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J. M., Shi, W., Égile, C., Ruiz-Soto, R., Laird, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2403 · Cited by 96
Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy
Xue, G., Zippelius, A., WICKI, A. N., Mandalà, M., Tang, F., Massi, D., & Hemmings, B. A. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv171 · Cited by 91
Self-citationClinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib
Ramanathan, S., Jin, F., Sharma, S., & Kearney, B. P. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0304-0 · Cited by 85
Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
Yi, K. H., & Lauring, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6648 · Cited by 77
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
Ohwada, J., Ebiike, H., Kawada, H., Tsukazaki, M., Nakamura, M., Miyazaki, T., Morikami, K., Yoshinari, K., Yoshida, M., Kondoh, O., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.065 · Cited by 73
Sweetlove, M., Wrightson, E., Kolekar, S., Rewcastle, G. W., Baguley, B. C., Shepherd, P. R., & Jamieson, S. M. F. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00135 · Cited by 71
PI3K in cancer–stroma interactions: bad in seed and ugly in soil
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A., & Martini, M. (2013) · Oncogene · doi:10.1038/onc.2013.265 · Cited by 70
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
O’Donnell, J. S., Smyth, M. J., & Teng, M. W. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0365-1 · Cited by 69
Self-citationSafety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
Tamura, K., Hashimoto, J., Tanabe, Y., Kodaira, M., Yonemori, K., Seto, T., Hirai, F., Arita, S., Toyokawa, G., Chen, L., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2987-9 · Cited by 66
A core of kinase-regulated interactomes defines the neoplastic MDSC lineage
Gato, M., de Morentin, X. M., Blanco‐Luquin, I., Fernández‐Irigoyen, J., Zudaire, I., Liechtenstein, T., Arasanz, H., Lozano, T., Casares, N., Chaikuad, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4746 · Cited by 60
Wisinski, K. B., Tevaarwerk, A. J., Burkard, M. E., Rampurwala, M. M., Eickhoff, J. C., Bell, M. C., Kolesar, J., Flynn, C. M., & Liu, G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2365 · Cited by 54
Burris, H. A., Siu, L. L., Infante, J. R., Wheler, J. J., Kurkjian, C. D., Opalinska, J., Smith, D. A., Antal, J. M., Gauvin, J., Gonzalez, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3003 · Cited by 50
González-Garcı́a, A., Sánchez-Ruíz, J., Flores, J. M., & Carrera, A. C. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.001 · Cited by 41
Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology
Teng, M. W. L., Ritchie, D. S., Neeson, P. J., & Smyth, M. J. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_50 · Cited by 37
Self-citationFirst-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
Banerji, U., Dean, E. J., Gonzalez, M., Greystoke, A., Basu, B., Krebs, M., Puglisi, M., Grinsted, L. M., Oelmann, E. M., Burke, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3004 · Cited by 32
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
Song, X., Fan, P., Bantikassegn, A., Guha, U., Threadgill, D. W., VARMUS, H. E., & Politi, K. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-1625 · Cited by 30
Perkins, M. R., Grande, S. M., Hamel, A., Horton, H. M., Garrett, T. E., Miller, S. M., Latimer, H. J., Horvath, C. J., Kuczewski, M., Friedman, K. M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1893.1893 · Cited by 27
Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?
Gao, Y., Yuan, C. Y., & Yuan, W. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.07.02 · Cited by 24
Cooper, Z. A., Reuben, A., Amaria, R. N., & Wargo, J. A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954956 · Cited by 19
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Branched Chain Amino Acids: Beyond Nutrition Metabolism
Nie, C., He, T., Zhang, W., Zhang, G., & Ma, X. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040954 · Cited by 786
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Myricetin: A review of the most recent research
Song, X., Tan, L., Wang, M., Ren, C., Guo, C., Yang, B., Ren, Y., Cao, Z., Li, Y., & Pei, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111017 · Cited by 378
Metadata
- Authors
- O’Donnell, J. S., Massi, D., Teng, M. W. L., & Mandala, M.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 48
- Pages
- 91-103
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2611933383
- Cited by
- 375
- References
- 112
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.